Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | ATM | Q13315 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | YAP1 | P46937 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6039069 | 1.00 | KMT2A (0.58) | KMT2AATMMEN1KLK5CACNA1B | |
| SCHEMBL17961959 | 0.90 | KMT2A (0.58) | KMT2AATMMEN1KLK5CACNA1B | |
| SCHEMBL16604444 | 0.90 | KMT2A (0.58) | KMT2AATMMEN1KLK5CACNA1B | |
| SCHEMBL16604420 | 0.90 | KMT2A (0.58) | KMT2AATMMEN1KLK5CACNA1B | |
| SCHEMBL28057010 | 0.90 | KMT2A (0.58) | KMT2AATMMEN1KLK5CACNA1B | |
| SCHEMBL17982930 | 0.90 | KMT2A (0.58) | KMT2AATMMEN1KLK5CACNA1B | |
| SCHEMBL16604442 | 0.90 | KMT2A (0.58) | KMT2AATMMEN1KLK5CACNA1B | |
| SCHEMBL18093204 | 0.90 | KMT2A (0.58) | KMT2AATMMEN1KLK5CACNA1B | |
| SCHEMBL16606803 | 0.85 | KMT2A (0.53) | KMT2AATMMEN1KLK5PLG | |
| SCHEMBL18011627 | 0.85 | KMT2A (0.53) | KMT2AATMMEN1KLK5PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014242-A1 | Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) | GERALD CHRISTOPHE P | 2006-01-19 | — | — | US | disclosed |
| US-6734182-B2 | SLEEP DISORDERS; EATING DISORDERS; SEXUAL DISORDERS; HYPOTENSIVE AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-05-11 | — | — | US | disclosed |
| US-6713265-B1 | MEASURING THE BINDING OF GTP GAMMA S TO CELLS EXPRESSING Y5 RECEPTOR IN THE PRESENCE AND IN THE ABSENCE OF COMPOUND OF INTEREST | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-03-30 | — | — | US | disclosed |
| US-6645774-B1 | Administering for treatment of obesity, bulimia or anorexia | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-20030013714-A1 | Aryl sulfonamides and sulfamide derivatives and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-01-16 | — | — | US | disclosed |
| US-6391877-B1 | EATING DISORDERS; SEXUAL DISORDERS; ANTIDEPRESSANTS; ANTIEPILEPTIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-05-21 | — | — | US | disclosed |
| US-6316203-B1 | MONITORING ACTIVITY OF NERVOUS SYSTEM LIGAND; INCUBATE LIGAND AND TRANSFECTED CELL, DETECT AMPLIFICATION IN BINDING PROTEIN ACTIVITY, AMPLIFICATION IN BINDING PROTEIN ACTIVITY INDICATES AGONIST | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-11-13 | — | — | US | disclosed |
| US-6211241-B1 | ANTIDEPRESSANTS, SLEEP AND EATING DISORDERS AND ANTIEPILEPTIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-03 | — | — | US | disclosed |
| US-5989920-A | RECEPTOR BINDING ASSAY FOR SCREENING DRUGS WHICH BIND TO HUMAN OR RAT Y5 RECEPTOR BY CONTACTING NONNEURONAL CELLS TRANSFECTED WITH VECTOR HAVING SEQUENCE CODING FOR RECEPTOR AND DETECTING BINDING; TREATMENT OF OBESITY, EATING DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-11-23 | — | — | US | disclosed |
| US-5968819-A | FOR MODIFYING FEEDING BEHAVIOR IN CONNECTION WITH EATING DISORDERS; FOR SCREENING ANTAGONISTS, AGONISTS; FOR PROBES TO DETECT RECEPTORS; ANTISENSE AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014242-A1 | Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) | NPY5R, NPY4R, NPY1R | KMT2A 699/4885ATM 4201/4885MEN1 2307/4885 |
| US-20030013714-A1 | Aryl sulfonamides and sulfamide derivatives and uses thereof | NPY5R, SSTR5, NPY2R | KMT2A 1117/4885ATM 4366/4885MEN1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.